185 related articles for article (PubMed ID: 32373648)
1. iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation.
Fleischer A; Vallejo-Díez S; Martín-Fernández JM; Sánchez-Gilabert A; Castresana M; Del Pozo A; Esquisabel A; Ávila S; Castrillo JL; Gaínza E; Pedraz JL; Viñas M; Bachiller D
Mol Ther Methods Clin Dev; 2020 Jun; 17():858-870. PubMed ID: 32373648
[TBL] [Abstract][Full Text] [Related]
2. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
[TBL] [Abstract][Full Text] [Related]
3. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations.
de Winter-de Groot KM; Berkers G; Marck-van der Wilt REP; van der Meer R; Vonk A; Dekkers JF; Geerdink M; Michel S; Kruisselbrink E; Vries R; Clevers H; Vleggaar FP; Elias SG; Heijerman HGM; van der Ent CK; Beekman JM
J Cyst Fibros; 2020 Jul; 19(4):614-619. PubMed ID: 31735562
[TBL] [Abstract][Full Text] [Related]
4. Guanylate cyclase 2C agonism corrects CFTR mutants.
Arora K; Huang Y; Mun K; Yarlagadda S; Sundaram N; Kessler MM; Hannig G; Kurtz CB; Silos-Santiago I; Helmrath M; Palermo JJ; Clancy JP; Steinbrecher KA; Naren AP
JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978796
[TBL] [Abstract][Full Text] [Related]
5. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
de Poel E; Spelier S; Hagemeijer MC; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Ithakisiou GN; Kruisselbrink E; Oppelaar H; Berkers G; de Winter de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; Bakker M; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Blaazer AR; Muijlwijk-Koezen JE; van der Ent CK; Beekman JM
J Cyst Fibros; 2023 May; 22(3):548-559. PubMed ID: 37147251
[TBL] [Abstract][Full Text] [Related]
6. CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy.
de Poel E; Spelier S; Korporaal R; Lai KW; Boj SF; Conrath K; van der Ent CK; Beekman JM
Front Mol Biosci; 2021; 8():698358. PubMed ID: 34604301
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
[TBL] [Abstract][Full Text] [Related]
8. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
[TBL] [Abstract][Full Text] [Related]
9. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
10. Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis.
Esposito S; Tosco A; Villella VR; Raia V; Kroemer G; Maiuri L
Mol Cell Pediatr; 2016 Dec; 3(1):13. PubMed ID: 26976279
[TBL] [Abstract][Full Text] [Related]
11. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM
Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259
[TBL] [Abstract][Full Text] [Related]
12. Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.
Cai Z; Palmai-Pallag T; Khuituan P; Mutolo MJ; Boinot C; Liu B; Scott-Ward TS; Callebaut I; Harris A; Sheppard DN
J Physiol; 2015 Jun; 593(11):2427-46. PubMed ID: 25763566
[TBL] [Abstract][Full Text] [Related]
13. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
14. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
16. rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice.
Vidović D; Carlon MS; da Cunha MF; Dekkers JF; Hollenhorst MI; Bijvelds MJ; Ramalho AS; Van den Haute C; Ferrante M; Baekelandt V; Janssens HM; De Boeck K; Sermet-Gaudelus I; de Jonge HR; Gijsbers R; Beekman JM; Edelman A; Debyser Z
Am J Respir Crit Care Med; 2016 Feb; 193(3):288-98. PubMed ID: 26509335
[TBL] [Abstract][Full Text] [Related]
17. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids.
Crawford DK; Mullenders J; Pott J; Boj SF; Landskroner-Eiger S; Goddeeris MM
J Cyst Fibros; 2021 May; 20(3):436-442. PubMed ID: 33558100
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Functional Analysis of CFTR and Other Apically Localized Proteins in iPSC-Derived Human Intestinal Organoids.
Xia S; Bozóky Z; Di Paola M; Laselva O; Ahmadi S; Jiang JX; Pitstick AL; Jiang C; Rotin D; Mayhew CN; Jones NL; Bear CE
Cells; 2021 Dec; 10(12):. PubMed ID: 34943927
[TBL] [Abstract][Full Text] [Related]
20. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.
Boj SF; Vonk AM; Statia M; Su J; Vries RR; Beekman JM; Clevers H
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
